Endo Pharmaceuticals

Endo became Endo Pharmaceuticals Inc. as a result of a management buyout from DuPont Merck in 1997. Endo is a specialty pharmaceutical company engaged in the research, development, sale and marketing of prescription pharmaceuticals used primarily to treat and manage pain.

Personnel

 * Chief financial officer: Charles A. Rowland Jr. (as of December 2006, replacing Jeff Black)
 * The company's sales force numbers 590

Products

 * Amantadine (Symmetrel®)
 * Carbidopa with levodopa (Carbidopa/Levodopa USP)
 * Frovatriptan (Frova®)
 * Hydrocodone with acetominophen (Zydone®)
 * Hydrocodone with homatropine (Hycodan®)
 * Lidocaine (Lidoderm®)
 * Lidocaine with tetracaine (Synera®)
 * Molindone (Moban®)
 * Oxycodone with acetominophen (Percocet®, Endocet®)
 * Oxycodone with aspirin (Percodan®)
 * Oxymorphone (Opana®)